Combined Electroacupuncture and Auricular Acupuncture for Persistent Insomnia: A Randomized Controlled Trial of Dose-Response Effect

The University of Hong Kong1 site in 1 country224 target enrollmentJuly 2012

ConditionsInsomnia

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Insomnia
Sponsor: The University of Hong Kong
Enrollment: 224
Locations: 1
Primary Endpoint: Changes of sleep parameters by subjective measures using sleep log
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a randomized controlled trial to evaluate the clinical efficacy of combined electro-acupuncture and auricular acupuncture for persistent Iinsomnia in the adult population in Hong Kong.

Detailed Description

Combined electro-acupuncture and auricular acupuncture is potential to be an alternative treatment for primary insomnia. The purpose of this study is to evaluate the clinical effectiveness of combined electroacupuncture and auricular acupuncture on persistent insomnia. This is a randomized double-blinded controlled trial. Patients will be randomly assigned to the electro-acupuncture group, the electro-acupuncture plus auricular acupuncture group or the waitlist controlled group. Patients will be put into groups and then compared.The chance of getting into each group is 3:3:1.

Registry

clinicaltrials.gov

Start Date

July 2012

End Date

May 2015

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

The University of Hong Kong

Responsible Party

Principal Investigator

Dr. Chung Ka-Fai

Clinical Associate Professor

The University of Hong Kong

Eligibility Criteria

Inclusion Criteria

•Aged 18 years or above
•Hong Kong residents
•Ethnic Chinese
•Meet the diagnosis criteria of presistent insomnia for at least 3 months according to Current Diagnostic and Statistical Manual of Mental Disorders (the proposed Fifth Edition)
•Insomnia more than 3 nights per week for at least 3 months
•Willing to give informed consent
•Able to comply with trial protocol

Exclusion Criteria

•Have a Hamilton Depression Rating Scale scores above 18
•Have sleep apnea or periodic limbs movement disorder detected by overnight polysomnography
•Have suicidal risk as assessed by the Hamilton Depression Rating Scale suicidal risk item
•Have current major depressive disorder, generalized anxiety disorders or panic disorder, manic or hypomanic episode, substance use disorders except caffeine and nicotine, organic mental disorder, schizophrenia or any other psychotic disorder
•Receiving psychotropic drugs with dosage changes in the last 4 weeks prior to screening, baseline or during the study
•Have valvular heart defects or bleeding disorders or were taking anticoagulant drugs
•Are pregnant, breast-feeding, or woman of childbearing potential not using adequate contraception
•Have any unstable psychiatric conditions or serious physical illnesses which are judged by the investigator to render unsuitable or unsafe
•Have infection or abscess close to the site of selected acupoints and in the investigator's opinion inclusion is unsafe
•Taking Chinese herbal medicine or over-the-counter drugs which are intending for insomnia within the last 2 weeks prior to baseline or during the study

Outcomes

Primary Outcomes

Changes of sleep parameters by subjective measures using sleep log

Time Frame: Baseline, 1-week posttreatment, 4-week posttreatment, and 13-week posttreatment

We will measure sleep parameters (including sleep onset latency, sleep efficiency, total sleep time, times of wakening during sleep) by subjective measures using sleep log. The measure is a composite outcome measure consisting of multiple measures

Secondary Outcomes

Change of subjects' sleep inhibitory behaviors measured by Sleep Hygiene Practice Scale (SHPS)(Baseline, 1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)
Change of self-rated sleep quality score measured by Insomnia Severity Index (ISI) questionnaire(Baseline, 1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)
Change of self-rated sleep quality score measured by the Pittsburgh Sleep Quality Index (PSQI) questionnaire(Baseline, 1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)
Change of anxiety and depression states measured by Hospital Anxiety and Depression Scale (HADS)(Baseline, 1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)
Change of subjects' functioning regarding work/study, social life and family measured by Sheehan Disability Scale (SDS)(Baseline, 1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)
Change of subjects' self-rated fatigue score measured by Multidimensional Fatigue Inventory (MFI)(Baseline, 1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)
Change of subjects' likeliness of dozing measured by Epworth Sleepiness Scale (ESS)(Baseline, 1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)
Change of subjects' sleep-related cognition measured by Dysfunctional Beliefs and Attitudes about Sleep (DBAS)(Baseline, 1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)
Change of subjects' credibility to the treatment measured by Credibility of treatment rating scale(Second and the last time of the treatment; 1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)
Change of sleep parameters (sleep onset latency, sleep efficiency, total sleep time, times of wakening during sleep) by objective measure - wrist actigraphy(Baseline, 1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)
Change of serious adverse events measured by Serious Adverse Event (SAE)(1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)
Change of potential adverse events related to acupuncture measured by Adverse Events Report Related to Acupuncture(1-week posttreatment, 4-week posttreatment, and 13-week posttreatment)